Skip to main content

Table 1 Available randomized trials regarding the use of letrozole during the follicular phase in IVF/ICSI cycles

From: Aromatase inhibitors in stimulated IVF cycles

  Pituitary downregulation protocol/groups Ovarian stimulation Patients (N) Clinical pregnancy rate (%) Implantation rate (%) Fertilization rate (%) No oocytes (mean) Total FSH dose (mean)
Normoresponders         
   Verpoest 2006 [9] Antagonist rFSH+letrozole 10 50 31.25 63.3 13.8 1575
  Antagonist rFSH 10 20 12.5 77.4 9.6 1650
Poor responders         
   Goswami 2004 [10] - rFSH+letrozole 13 23 NA NA 1.6 150
  Agonist rFSH 25 24 NA NA 2.1 2865
   Garcia-Velasco 2005 [4] Antagonist rFSH+ HMG+ letrozole 71 22.4 25 68.2 6.1 3627
  Antagonist rFSH+ HMG 76 15.2 9.4 63.3 4.3 3804
   Ozmen 2009 [11] Antagonist rFSH+letrozole 35 28.6 NA 92.4 4.9 2980
  Antagonist rFSH 35 17.1 NA 97.2 4.8 3850
   Davar 2010 [12] Antagonist rFSH/HMG + letrozole 45 4.4 3.8 67.3 2.8 3158
  Agonist rFSH or HMG 49 12.3 7.7 70.7 4.4 3458
  1. N, number; NA, not data available